Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case

• Main Authors: Emilie Talagrand-Reboul, Benoit Westermann, Matthieu A. Raess, Gilles Schnell, Paola Cantero, Cathy Barthel, Laurence Ehret-Sabatier, Benoit Jaulhac, Nathalie Boulanger
• Format: Article
• Language: English
• Published: MDPI AG 2020-08-01
• Series: Vaccines
• Subjects: tick-borne diseases; Lyme; <i>Borrelia</i>; proteomics; skin; markers of infection
• Online Access: https://www.mdpi.com/2076-393X/8/3/463

Tick-borne diseases affecting humans and animals are on the rise worldwide. Vaccines constitute an effective control measure, but very few are available. We selected Lyme borreliosis, a bacterial infection transmitted by the hard tick <i>Ixodes</i>, to validate a new concept to identify vaccine candidates. This disease is the most common tick-borne disease in the Northern Hemisphere. Although attempts to develop a vaccine exist, none have been successfully marketed. In tick-borne diseases, the skin constitutes a very specific environment encountered by the pathogen during its co-inoculation with tick saliva. In a mouse model, we developed a proteomic approach to identify vaccine candidates in skin biopsies. We identified 30 bacterial proteins after syringe inoculation or tick inoculation of bacteria. Discovery proteomics using mass spectrometry might be used in various tick-borne diseases to identify pathogen proteins with early skin expression. It should help to better develop sub-unit vaccines based on a cocktail of several antigens, associated with effective adjuvant and delivery systems of antigens. In all vector-borne diseases, the skin deserves further investigation to better define its role in the elaboration of protective immunity against pathogens.